Medicure Announces Q1 2025 Financial Results and Director Election Outcomes

Medicure Inc., involved in the promotion and distribution of pharmaceuticals in the U.S., announced its Q1 2025 financial results. Total net revenue was $5.5 million, slightly down from $5.7 million in Q1 2024. Revenue from AGGRASTAT® decreased to $1.7 million due to increased competition, whereas revenue from Marley Drug business rose to $3.1 million, driven by higher product sales.

The election results at the annual shareholders meeting were also disclosed, with all nominated directors re-elected by over 99% votes.

The company reported a net loss of $694,000, contrasted with a net income of $51,000 in the previous year. Factors contributing included decreased AGGRASTAT revenue and increased costs. Cash reserves grew to $7.2 million, up from $6.1 million in 2024.

Medicure plans to broaden its pharmacy offerings, including ZYPITAMAG, through its newly acquired Gateway Pharmacy.